The evolving burden of early-onset Alzheimer's disease and other dementias in BRICS countries: Insights from the Global Burden of Disease Study 2023 and projections to 2035
Restricted accessResearch articleFirst published online 2026
The evolving burden of early-onset Alzheimer's disease and other dementias in BRICS countries: Insights from the Global Burden of Disease Study 2023 and projections to 2035
The burden of early-onset Alzheimer's disease and other dementias (EOAD) in BRICS nations (Brazil, Russia, India, China, South Africa, Egypt, Ethiopia, Iran, Saudi Arabia, the United Arab Emirates, and Indonesia) is poorly characterized.
Objective
Our aims are to characterize national trends, identify high-burden populations, quantify sex- and risk factor-specific burdens, and inform targeted prevention and age-inclusive healthcare strategies in these key nations.
Methods
Using data from the Global Burden of Disease Study (GBD) 2023, we analyzed EOAD (ages 40–64) across BRICS countries from 1990–2023, employing decomposition, Joinpoint regression, and Bayesian Age-Period-Cohort modeling to project trends to 2035.
Results
Prevalent cases increased in all nations, led by China. Age-standardized incidence rose in China (average annual percentage change 0.461%) but declined in India and Iran. Females consistently bore a higher burden. Ambient particulate matter drove substantial disability-adjusted life years in Iran (74.43/100,000) and Saudi Arabia, while household air pollution was key in Ethiopia and India. Projections indicate divergence by 2035, with Russia's incidence rising to 56.22 and Saudi Arabia's prevalence falling to 160.10 per 100,000.
Conclusions
EOAD burden in BRICS is heterogeneous, driven by aging, sex, and modifiable risks, necessitating tailored public health strategies.
ZhuWYuXHuangC, et al.Trends and inequalities in the global burden of Alzheimer’s disease and other dementias, 1990–2021: a Chinese perspective. BMC Public Health2025; 25: 2977.
2.
HarapanHZhangQDengY, et al.Global trends in Alzheimer’s disease and other dementias in adults aged 55 and above (1992–2021): an age-period-cohort analysis based on the GBD 2021. PLoS One2025; 20: e0331204.
3.
ZhangXLuHXiongJ. Incidence trends and age-period-cohort analysis of Alzheimer’s disease and other dementias in the world and China from 1990 to 2021: analyses based on the Global Burden of Disease Study 2021. Front Neurol2025; 16: 1628577.
4.
HaoMChenJ. Trend analysis and future predictions of global burden of Alzheimer’s disease and other dementias: a study based on the global burden of disease database from 1990 to 2021. BMC Med2025; 23: 378.
5.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
6.
ChenSCaoZNandiA, et al.The global macroeconomic burden of Alzheimer's disease and other dementias: estimates and projections for 152 countries or territories. Lancet Glob Health2024; 12: e1534–e1543.
7.
XiaopengZJingYXiaL, et al.Global burden of Alzheimer's disease and other dementias in adults aged 65 years and older, 1991–2021: population-based study. Front Public Health2025; 13: 1585711.
8.
HeZZhangHHuG, et al.The current status, trends, and challenges of Alzheimer’s disease and other dementias in Asia (1990–2036). Front Public Health2025; 13: 1583339.
9.
Tahami MonfaredAAByrnesMJWhiteLA, et al.Alzheimer’s disease: epidemiology and clinical progression. Neurol Ther2022; 11: 553–569.
10.
NudelmanKNHJacksonTRumbaughM, et al.Pathogenic variants in the Longitudinal Early-onset Alzheimer’s Disease Study cohort. Alzheimers Dement2023; 19: S64–S73.
11.
RayNRAyodeleTJean-FrancoisM, et al.The Early-onset Alzheimer's Disease Whole-Genome Sequencing Project: study design and methodology. Alzheimers Dement2023; 19: 4187–4195.
12.
MehtaRIKeithCMTeixeiraCVL, et al.The early-onset Alzheimer’s disease MRI signature: a replication and extension analysis in early-stage AD. Cereb Cortex2024; 34: bhae475.
13.
SirkisDWBonhamLWJohnsonTP, et al.Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease. Mol Psychiatry2022; 27: 2674–2688.
14.
QinWLiFYLiuWY, et al.The genetic landscape of early-onset Alzheimer's disease in China. Alzheimers Dement2025; 21: e14486.
15.
Tort-MerinoAFalgàsNAllenIE, et al.Early-onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late-onset. Ann Clin Transl Neurol2022; 9: 1962–1973.
16.
AskenBMWangWEAriasF, et al.Sex and ethnicity in early-onset Alzheimer's disease biomarkers and global function. Alzheimers Dement (Amst)2025; 17: e70157.
17.
TroutwineBRHamidLLysakerCR, et al.Apolipoprotein E and Alzheimer's disease. Acta Pharm Sin B2022; 12: 496–510.
18.
ZhengQWangX. Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell2025; 16: 83–120.
19.
InguanzoAPoulakisKOltraJ, et al.Atrophy trajectories in Alzheimer’s disease: how sex matters. Alzheimers Res Ther2025; 17: 79.
20.
LogueMWMillerMWShervaR, et al.Alzheimer's disease and related dementias among aging veterans: examining gene-by-environment interactions with post-traumatic stress disorder and traumatic brain injury. Alzheimers Dement2023; 19: 2549–2559.
21.
LoikaYLoikoECulminskayaI, et al.Pleiotropic associations with Alzheimer’s disease and physical activity: sex differences and the effects of environment. Int J Mol Sci2024; 25: 12571.
22.
ByrdDRMartinDAJosephRP.Environmental, sociocultural, behavioral, and biological factors associated with cognitive decline, Alzheimer's Disease, and other types of dementia in Black Americans. Curr Epidemiol Rep2023; 10:252–263.
23.
SyedaTCannonJR. Environmental exposures and the etiopathogenesis of Alzheimer's disease: the potential role of BACE1 as a critical neurotoxic target. J Biochem Mol Toxicol2021; 35: e22694.
24.
FalcónCGasconMMolinuevoJL, et al.Brain correlates of urban environmental exposures in cognitively unimpaired individuals at increased risk for Alzheimer's disease: a study on Barcelona's population. Alzheimers Dement (Amst)2021; 13: e12205.
25.
O’PielaDRDurisekGREscobarY-NH, et al.Particulate matter and Alzheimer’s disease: an intimate connection. Trends Mol Med2022; 28: 770–780.
26.
ShimJ-IByunGLeeJ-TT. Long-term exposure to particulate matter and risk of Alzheimer’s disease and vascular dementia in Korea: a national population-based cohort study. Environ Health2023; 22: 35.
27.
CaseyELiZLiangD, et al.Association between fine particulate matter exposure and cerebrospinal fluid biomarkers of Alzheimer’s disease among a cognitively healthy population-based cohort. Environ Health Perspect2024; 132: 47001.
28.
KosyrevaASentyabrevaATsvetkovI, et al.Alzheimer’s disease and inflammaging. Brain Sci2022; 12: 1237.
29.
OnyangoIGJaureguiGVČarnáM, et al.Neuroinflammation in Alzheimer’s disease. Biomedicines2021; 9: 524.
ParkHNiMLeY. Neuroinflammation and nutrition in Alzheimer’s disease. Front Neurol2025; 16: 1622571.
32.
DangMLiYZhaoL, et al.Causal association between particulate matter 2.5 and Alzheimer’s disease: a Mendelian randomization study. Front Public Health2024; 12: 1343915.
33.
MichailidisMMoraitouDTataDA, et al.Alzheimer’s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer’s disease and type 2 diabetes. Int J Mol Sciences2022; 23: 2687.
34.
YuanYZhaoGZhaoY. Dysregulation of energy metabolism in Alzheimer's disease. J Neurol2024; 272: 2.
35.
PengYYaoSYChenQ, et al.True or false? Alzheimer’s disease is type 3 diabetes: evidences from bench to bedside. Ageing Res Rev2024; 99: 102383.
36.
MengXZhangHZhaoZ, et al.Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies. Mol Med2025; 31: 61.
37.
AtabiFMoassesfarMNakhaieT, et al.A systematic review on type 3 diabetes: bridging the gap between metabolic dysfunction and Alzheimer’s disease. Diabetol Metab Syndr2025; 17: e2201882.
